Elekta’s New Radiation Oncology Technology to Shape the Future of Cancer Care

Worldwide unveiling of radiation delivery technology will be held March 1 in Atlanta, USA

STOCKHOLM and ATLANTA, February 4 – At an exclusive event scheduled March 1, 2013, Elekta will reveal a leap forward in radiation oncology and the care of individuals with cancer worldwide.

Founded in 1972, Elekta was the first to bring a completely digital linear accelerator to the market, as well as the first to fully integrate imaging technology in the treatment system. Elekta is a market-leading developer of cancer care and neuroscience solutions, including a world-class portfolio of linear accelerators, dedicated radiosurgery and brachytherapy systems and oncology information and treatment planning software solutions.

“At Elekta, we are united by a passion that drives us to constantly strive toward the development of new cancer care solutions that benefit patients, caregivers and healthcare systems,” says Elekta’s President and CEO Tomas Puusepp. “It is this unrelenting dedication to patients and their healthcare providers that has inspired our efforts to create a truly singular technological solution in radiation oncology.”

The worldwide unveiling event will be held Friday, March 1 at the Renaissance Atlanta Waverly Hotel, Atlanta, Georgia, USA, 11:00-12:00 EST (17:00-18:00 CET). To attend or view live online, register at www.elekta.com/revealed.

Following the unveiling event, Elekta will host an investor telephone conference with President and CEO Tomas Puusepp on March 1, 12:30 EST (18:30 CET).

To take part in the conference call, please dial in about 5-10 minutes in advance and use the access code 927782.

  • Swedish dial-in number: +46 (0)8 5052 0110
  • UK dial-in number: +44 (0)20 7162 0077
  • US dial-in number: +1 877 491 0064

The telephone conference will also be broadcasted over the internet (audio only). Please use the link: http://webeventservices.reg.meeting-stream.com/73936_elekta/

The above information is such that Elekta AB (publ) shall make public in accordance with the Securities Market Act and/or the Financial Instruments Trading Act. The information was published at 07:30 CET on February 4, 2013.

Availability of product will be subject to local regulatory clearance.

# # #

The above information is such that Elekta AB (publ) shall make public in accordance with the Securities Market Act and/or the Financial Instruments Trading Act. The information was published at 07:30 CET on February 4, 2013.

About Elekta

Elekta is proud to be the leading innovator of equipment and software used to improve, prolong and save the lives of people with cancer and brain disorders. Our advanced, effective solutions are created in collaboration with customers, and more than 6,000 hospitals worldwide rely on Elekta technology. Our treatment solutions and oncology informatics portfolios are designed to enhance the delivery of radiation therapy, radiosurgery and brachytherapy, and to drive cost efficiency in clinical workflows. Elekta employs 3,600 people around the world. Headquartered in Stockholm, Sweden, Elekta is listed on NASDAQ Stockholm. www.elekta.com.

Press Releases

Downloads

  PDF Version

For further information, please contact

Johan Andersson Melbi, Director, Investor Relations, Elekta ABTel: +46 702 100 451
Email: johan.anderssonmelbi@elekta.comTime zone: CET: Central European Time

Michelle Joiner, Director, Global Public Relations and Brand Management, ElektaTel: +1 770-670-2447
Email: michelle.joiner@elekta.comTime zone: ET: Eastern Time